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OBJECTIVE — ToexplorerelationshipsbetweenC-reactiveprotein(CRP),subclinicalinfec-
tion, insulin resistance, and metabolic syndrome.
RESEARCH DESIGN AND METHODS — Data from 1,174 Eskimos, aged 18 years,
from the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study were ana-
lyzed; 40 participants with diabetes were eliminated. Baseline assessment included interviews,
physical exam, and blood and urine sampling. Metabolic syndrome was assessed using Adult
Treatment Panel III criteria. CRP and antibodies to common pathogens were measured.
RESULTS — Although CRP was related in univariate analyses to insulin resistance and met-
abolic syndrome, relations were attenuated or eliminated after adjustment for relevant covari-
ates.CRPwasnothigheramongthosewithimpairedfastingglucose(IFG),andpathogenburden
was not related to insulin resistance, metabolic syndrome, or IFG.
CONCLUSIONS — Pathogen burden and inﬂammation do not seem to be related to insulin
resistance,metabolicsyndrome,orIFGinthispopulation.Theinﬂammatoryprocessmayreﬂect
insulin resistance or its correlates but most likely is not causative.
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I
nsulinresistance,metabolicsyndrome,
and diabetes are associated with in-
ﬂammation (1–3). It is unclear, how-
ever, whether the inﬂammatory process
causes insulin resistance and accelerates
progression to diabetes or whether insu-
lin resistance and diabetes increase in-
ﬂammation.WhileAlaskanEskimoshave
high rates of cardiovascular disease (4)
and subclinical infection (5), diabetes, in-
sulin resistance, and metabolic syndrome
occur less often than in U.S. whites (6).
Therefore, exploration of the relation-
ships between subclinical infection, in-
ﬂammatory markers, insulin resistance,
and diabetes in this population may illu-
minate possible mechanisms.
RESEARCH DESIGN AND
METHODS— The Genetics of Coro-
nary Artery Disease in Alaska Natives
(GOCADAN) study population includes
EskimosresidingintheNortonSoundre-
gion of Alaska. Of this population, 1,214
family members, aged 18 years, were
recruited (October 2000–April 2004)
(7). Questionnaires provided demo-
graphic, health habits, and medical his-
tory data. Sitting blood pressure was
measured, and the mean of the second
and third measurements was used for
analysis. Fasting blood measures in-
cluded glucose, insulin, ﬁbrinogen, high-
sensitivity C-reactive protein (CRP), and
homocysteine (HCY) (7). Dietary intake
was assessed using a food-frequency
questionnaire validated for Alaska Na-
tives (8).
IgG, IgA, and IgM antibodies to C.
pneumoniae and IgG antibodies to other
pathogens were determined using com-
mercially available enzyme-linked immu-
nosorbent assay (ELISA) kits (5). Obesity
was deﬁned as BMI 30 kg/m
2, meta-
bolic syndrome was deﬁned by Adult
Treatment Panel III criteria, and insulin
resistance was deﬁned by homeostasis
model assessment (HOMA) (9). Diabetes
and impaired fasting glucose (IFG) were
deﬁned by American Diabetes Associa-
tion criteria. Participants wore a Digi-
walker pedometer for 7 days.
Excluded from this study were 10
men and 30 women with diabetes. Partic-
ipant characteristics were compared us-
ing the Kruskal-Wallis test, Pearson’s 
2
test,Wilcoxon’srank-sumtest,orFisher’s
exact test. ANOVA was used to compare
least-squaremeansofinsulinresistanceor
IFG, as estimated by HOMA of insulin
resistance (HOMA-IR), for each quartile
of CRP and HCY and number of subclin-
ical infections. Logistic regression was
used to compute adjusted odds ratios of
metabolic syndrome across CRP or HCY
quartiles (using the ﬁrst quartile as the
reference) and levels of subclinical infec-
tion (using levels 1 and 2 as the refer-
ence). For each analysis, data were ﬁrst
adjusted for age and sex and then ana-
lyzed in models including BMI, alcohol
use,smokingstatus,physicalactivity,and
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(ANOVA and logistic regression), the
transformed variables for HOMA-IR and
CRP were used. Participants with CRP
10 mg/l (n  21 [1.7%]) were excluded
from CRP analyses. Because participants
were members of extended families, kin-
ship was accounted for in additional
analyses.
RESULTS— Of the 1,174 participants
(55% women), mean BMI was 27.5 kg/
m
2, 31.5% were overweight, and 29.1%
were obese. Metabolic syndrome was
present in 14.3% (11% men, 17%
women). Insulin was low (median 8.1
U/ml). Mean CRP was 1.6 mg/l (median
0.9mg/l),andmeanHCYwas7.3mol/l.
Measures for ﬁve common pathogens av-
eraged 3.4 per participant, and CRP was
positively correlated with pathogen bur-
den (P  0.02). BMI, percent women,
IFG (in women), CRP, glucose, insulin,
and waist circumference were higher and
current smoking, drinking, and physical
activitywerelowerwithincreasingtertiles
of HOMA-IR or in metabolic syndrome
(all P  0.001).
With increasing quartiles of CRP in
the simple models (Table 1), there was a
signiﬁcant increasing trend in HOMA-IR
(P  0.0001) and in probabilities of met-
abolic syndrome and IFG (P  0.0001
and 0.003, respectively). However, in the
multivariate models, relations between
HOMA-IR, metabolic syndrome, IFG,
and CRP were not signiﬁcant (P  0.341,
0.137, and 0.379, respectively). Relation-
ships of pathogen burden with HOMA-
IR, metabolic syndrome, and IFG were
not signiﬁcant in the simple or multivar-
iate models. For HCY, neither model was
signiﬁcant.
CONCLUSIONS— GOCADAN pro-
vides a unique setting for exploring rela-
tionships between inﬂammation, insulin
resistance, and metabolic syndrome.
Obesityisnotpervasive,diabetesratesare
low, rates of insulin resistance and other
metabolic syndrome components vary,
and chronic inﬂammation is prevalent in
the population. Although CRP in univar-
iatecomparisonswashigherinthosewith
insulin resistance and metabolic syn-
drome, pathogen burden was not. After
adjustment for confounders, no consis-
tent relationships were observed between
HOMA-IR, metabolic syndrome, or IFG
and CRP or subclinical pathogen burden.
Low-grade chronic inﬂammation has
been shown in vitro to promote insulin
resistance (10). Although cross-sectional
studies have demonstrated relationships
between CRP and measures of insulin re-
sistance or metabolic syndrome (11–13),
longitudinal studies have varied, with
CRP predictive of diabetes in some stud-
ies (14,15) but not others (3,13). In the
Insulin Resistance and Atherosclerosis
Study(IRAS),MonitoringTrendsandDe-
terminants in Cardiovascular Disease
(MONICA) study, Augsburg study, and
Atherosclerosis Risk in Communities
(ARIC) study, odds of diabetes with in-
creasing CRP became nonsigniﬁcant after
adjustment for BMI or other covariates
(3,13,14), suggesting that elevations in
inﬂammatory markers seen in insulin re-
sistance, metabolic syndrome, and diabe-
tes are not causative but a consequence of
theseabnormalities.Some(15)arguethat
inclusion of BMI in the models represents
an overadjustment, proposing that in-
ﬂammation precedes obesity; however,
until a causal relationship has been estab-
lished, it seems prudent to focus on the
complete models.
The lack of a relationship between
chronic inﬂammation and insulin resis-
tance and/or metabolic syndrome in this
population is supported by the observa-
tion that, despite chronic subclinical in-
fection,thispopulationhaslowincidence
of insulin resistance and diabetes. As in
other populations, diabetes is associated
with the female sex, obesity, and greater
insulin resistance (6); CRP is positively
associated with BMI and is higher with
diabetes, smoking, and increasing patho-
gen burden (data not shown); thus, CRP
appears to be an indicator of chronic in-
ﬂammation.Thereasonsforthehighsub-
clinical pathogen burden are unclear;
they may be related to conﬁnement in
close quarters in winter and lack of ade-
quate medical care.
This study is limited by its cross-
sectional design. Also, the high preva-
lenceofsubclinicalinfectionmayobscure
relationships between obesity and insulin
resistance on secretion of inﬂammatory
cytokines. Finally, inﬂammatory media-
tors other than CRP that were not mea-
sured may be mediators.
Insummary,whileanalysesofunique
populations often lead to unexpected
Table 1—Relationships among HOMA-IR, metabolic syndrome, IFG, CRP, and pathogen burden, the GOCADAN study
HOMA-IR Metabolic syndrome IFG
Model 1* Model 2† Model 1* Model 2† Model 1* Model 2†
CRP quartile
1 1.58  1.04 1.62  1.05 1 (referent) 1 (referent) 1 (referent) 1 (referent)
2 1.75  1.04 1.63  1.06 1.91 (0.90–4.07) 1.90 (0.56–6.43) 1.59 (0.81–3.11) 2.01 (0.57–7.11)
3 1.91  1.04 1.66  1.06 4.58 (2.29–9.14) 3.51 (1.14–10.85) 2.55 (1.37–4.76) 2.81 (0.86–9.12)
4 2.04  1.04 1.73  1.06 6.47 (3.30–12.72) 2.82 (0.92–8.67) 2.80 (1.51–5.17) 2.43 (0.75–7.84)
P 0.0001 0.341 0.0001 0.137 0.003 0.379
Pathogen burden
1 1.90  1.11 1.59  1.13 1 (referent) 1 (referent) — —
2 1.97  1.06 1.81  1.07 0.87 (0.29–2.60) 0.64 (0.11–3.71) 1 (referent)‡ 1 (referent)‡
3 1.79  1.03 1.83  1.04 0.83 (0.30–2.25) 0.69 (0.15–3.23) 0.78 (0.44–1.40) 0.94 (0.32–2.72)
4 1.84  1.03 1.78  1.04 0.98 (0.36–2.66) 0.70 (0.15–3.35) 0.88 (0.50–1.56) 1.08 (0.39–3.02)
5 1.74  1.06 1.62  1.07 0.73 (0.25–2.15) 0.44 (0.08–2.37) 0.70 (0.35–1.40) 0.89 (0.27–2.93)
P 0.562 0.368 0.831 0.831 0.7118 0.9643
Data are least-square means  SEM or odds ratio (95% CI). N  1,174 participants included in the analysis. *Adjusted for age and sex. †Adjusted for age, sex, BMI,
current smoking, current drinking, physical activity, n-3 fatty acid intake, and pathogen burden (in the CRP model). ‡Categories 1 and 2 combined as reference
category.
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standingofcomplexdisorders.Ourstudy
provides evidence that the inﬂammatory
process may reﬂect diabetes or insulin re-
sistance but is most likely not their cause
and suggests that subclinical infection
should be considered in further explora-
tions of the inﬂammatory process in peo-
ple with insulin resistance or metabolic
syndrome.
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